Directly Observed Weekly Fluoxetine for Major Depressive Disorder Among Hemodialysis Patients: A Single-Arm Feasibility Trial.

ABSTRACT:

Rationale & objective

Major depressive disorder (MDD) is common among hemodialysis patients, but treatment can add to their pill burden and may be limited by nonadherence. We sought to investigate the value of directly observed, once-weekly fluoxetine dosing in MDD.

Study design

Feasibility trial of adult hemodialysis patients with untreated MDD. The diagnosis of MDD was determined using the Mini International Neuropsychiatric Interview.

Setting & participants

16 patients at 15 hemodialysis facilities in Northeast Ohio.

Intervention

Patients were initially prescribed 20 mg of fluoxetine once daily for 2 weeks to assess their tolerance. The patients took this daily fluoxetine unobserved at home. They were then transitioned to 90 mg of fluoxetine once weekly for

SUBMITTER: Kauffman KM 

PROVIDER: S-EPMC8978139 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature